I accept the Minister’s points, but my concern remains that if in 10 years we have simvastatin in its current form versus a new name that is just a tweaked simvastatin at a thousand times the price, doctors will, under GMC rules, have to go for the one with the licence, as opposed to the off-patent one, even if it is in the BNF. I accept that the BNF mechanism will absolutely increase usage, but we still need to consider the longer term, given that in the future we might have huge numbers of off-patent drugs with new purposes.
Access To Medical Treatments (Innovation) Bill
Proceeding contribution from
Philippa Whitford
(Scottish National Party)
in the House of Commons on Friday, 29 January 2016.
It occurred during Debate on bills on Access To Medical Treatments (Innovation) Bill.
About this proceeding contribution
Reference
605 c547 Session
2015-16Chamber / Committee
House of Commons chamberSubjects
Librarians' tools
Timestamp
2021-11-04 13:29:53 +0000
URI
http://hansard.intranet.data.parliament.uk/Commons/2016-01-29/16012937000147
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2016-01-29/16012937000147
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2016-01-29/16012937000147